Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number to the paper to t

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

Application Number	PCT/EP2004/010845
Filing Date	23 September 2004
First Named Inventor	Christopher Norbert JOHNSON
Title	NOVEL COMPOUNDS
Art Unit	
Examiner Name	
Attorney Docket Number	PB60516

I hereby appoint:			
Practitioners associated with the Customer Numbers.	20462		
Or	20,102		
☐ Practitioner(s) named below:			
Name	Registration Number		
As my/our attorney(s) or agent(s) to prosecute the application	identified above, and to transact all business in the		
United States Patent and Trademark Office connected therewith.			
Please recognize or change the correspondence address for the above-identified application to:			
☐ The address associated with the above-mentioned Customer Number:			
Or			
E The address associated with Customer Number 20462			
Or			
☐ Firm or Individual Name:			
Address:			
Address:			
City:	State: Zip:		
Country:			
Telephone:	Fax:		
I am the:			
Applicant/Inventor:			
Assignee or record of the entire interest. See 37 CFR 3.71.			
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)			
SIGNATURE of Applicant or Assignee of Record			
Signature: Date	- 1 3 3AIV E003		
Name: Peter John GIDAINGS \ Telephone: +44 20 8047 4414			
Title and Company: Attorney and Authorised Official, Glaxo Group Limited			
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.			
*Total of: forms are submitted.	SEE DEIOW .		

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CRF 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

10/572671

IAPO REC'OPCTIPTO 20 MAR 2006

PTO/SB/81 (06-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

STATEMENT UNDER 37 CRF 3.73(b)		
Applicant/Patent Owner: Glaxo Group Limited		
International Application No./Patent No.: PCT/EP2004/010845 Filed/Issue Date: 23 September 2004		
Entitled: NOVEL COMPOUNDS		
Glaxo Group Limited, a corporation, states that it is:		
1. E the assignee of the entire right, title, and interest; or		
2. an assignee of less than the entire right, title and interest.		
The extent (by percentage) of its ownership interest is% in the patent application/patent identified above		
by virtue of either;		
A. [] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was		
recorded in the United States Patent and Trademark Office at Reel, Frame, or for which		
copy thereof is attached.		
OR		
B. [] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee		
as shown below:		
From: To: The document was recorded in the United States Patent and Trademark Office at		
Reel , Frame , or for which a copy thereof is attached. 2. From: To:		
2. From: To: To: The document was recorded in the United States Patent and Trademark Office at		
The document was recorded in the United States Patent and Trademark Office at		
Reel , Frame , or for which a copy thereof is attached. 3. From: To:		
The document was recorded in the United States Patent and Trademark Office at		
Reel , Frame , or for which a copy thereof is attached.		
[] Additional documents in the chain of title are listed on a supplemental sheet.		
[X] Copies of assignments or other documents in the chain of title are attached.		
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment		
Division in accordance with 37 CRF Part 3, if the assignment is to be recorded in the records of the USPTO.		
See MPEP 302.08]		
The undersigned (who still is supplied below) is authorized to act on behalf of the assignee.		
· / 1/1//1 N/ /		
2 0 JAN 2005		
Signature Date		
Date		
Peter John GIDDINGS +44 20 8047 4414		
Printed or Typed Name Telephone Number		
•		
Attorney and Authorised Official		
Title		

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CRF 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ASSIGNMENT

WHEREAS I/WE, Christopher Norbert JOHNSON, Stephen Frederick MOSS and David R WITTY of Harlow, Essex, GB (hereinafter called "the inventor(s)") have invented or discovered " NOVEL COMPOUNDS " (hereinafter called "the invention") for which a patent application no. 0322510.9 was filed on 25 September 2003 in the United Kingdom and for which an international patent application is now being filed designating the United States of America. I/we hereby authorize and request that the filing date and PCT International application, when known, be inserted here in parentheses;

(PCT/EP2004/010845 filed 23 September 2004)

WHEREAS the invention, being made in the course of my employment, belongs to my/our employer, namely GLAXOSMITHKLINE SERVICES UNLIMITED a company incorporated in England and Wales whose registered address is 980 Great West Road, Brentford, Middlesex TW8 9GS, England, and

WHEREAS GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED, a company incorporated in England and Wales whose registered address is 980 Great West Road, Brentford, Middlesex TW8 9GS, England, is desirous of acquiring from GLAXOSMITHKLINE SERVICES UNLIMITED the whole right, title and interest in and to the invention and the application, and

GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED have authorised and requested my/our making the application, and

WHEREAS GLAXO GROUP LIMITED a company organised and existing under and by virtue of the laws of England and Wales and having its principal place of business at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England, is desirous of acquiring from GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED the whole right, title and interest in

and to the invention and the application in respect of the United States of America;

NOW, THEREFORE, to all whom it may concern be it known that I/we, the inventor(s), hereby confirm the ownership by GLAXOSMITHKLINE SERVICES **UNLIMITED** of the invention and the application by operation of law and, if under the law of the United States of America I/we the inventor(s) have any ownership right, title and interest in the invention and the application (which I/we do not believe to be the case and claim no ownership right, title or interest in the invention and the application based on the law of the United Kingdom), I/we the inventor(s) nevertheless hereby assign and transfer such ownership right, title and interest in and to the invention and the application to GLAXOSMITHKLINE SERVICES UNLIMITED. GLAXOSMITHKLINE SERVICES UNLIMITED in turn hereby assigns and transfers to GLAXOSMITHKLINE RESEARCH AND **DEVELOPMENT LIMITED** its whole right, title and interest in and to the invention and the application. GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED in turn hereby assigns and transfers to GLAXO GROUP LIMITED its whole right, title and interest in and throughout the United States of America in and to the invention and the application and in and to any priority rights in respect of the invention and the application and in and to any divisional application, continuation or continuation in part application thereof, and in and to any extension or re-issue thereof, and I/we the inventor(s) and GLAXOSMITHKLINE and GLAXOSMITHKLINE SERVICES UNLIMITED RESEARCH **DEVELOPMENT LIMITED** hereby authorise and request any patent arising therefrom in the United States of America be issued to GLAXO GROUP LIMITED.

AND GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED hereby, and I/we the inventor(s) for myself/ourselves and my/our respective executors and legal representatives hereby, agree to provide information and make execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in GLAXO GROUP

LIMITED, its successors and assigns, the whole right, title and interest in and to the invention and the application hereby assigned and transferred in respect of the United States of America.

IN WITNESS whereof and with effect from 25 September 2003 the inventor(s) and Peter John GIDDINGS as Attorney of both GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED by virtue of Powers of Attorney granted by GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED respectively have hereunto set their respective hands.

SIGNED by Christopher Norbert JOHNSON:	Christophen Natherth	
SIGNED by Christopher Norbert Johnson.		
Date: 6th December 2004		
SIGNED by Stephen Frederick MOSS:	John Forderd W	
Date: 3d December 2004	-	
SIGNED by David R WITTY:	Dans N. Wolles	
Date: 3 Decembre wood		
SIGNED by Peter John GIDDINGS as the	ne Attorney of each of	
GLAXOSMITHKLINE SERVICES UNLIMITED	and GLAXOSMITHKLINE	
RESEARCH AND DEVELOPMENT LIMITED:		

1 9 JAN 2005